Influence of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects
Status:
Terminated
Trial end date:
2017-04-27
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the Carboxipeptidase D (CPD) genotyping as
a predictive biomarker of body weight and/or fat mass reduction in obese patients treated
with perindopril.
There is nonclinical and clinical evidence that a subgroup of human subjects may present a
decrease in body weight and/or fat mass following treatment with perindopril. Although the
individual characteristics that determine such effect are still unknown, Gene PreDiT SA
(Biocant Park, Cantanhede, Portugal) discovered that certain genetic characteristics (e.g.,
single nucleotide polymorphisms (SNPs) of CPD gene) may play a role and potentially could
serve as a potential predictive biomarker of response to perindopril.
These promising results, along with the fact that perindopril is a medicine already in use in
clinical practice, led Gene PreDiT SA to decide to proceed with the development of a
theranostic approach for the treatment of obesity. Such theranostic approach consists on the
use of CPD genotyping to identify obese subjects that could present improved body weight and
fat mass reduction following treatment with perindopril.
The current clinical trial aims to prove the concept and provide data to design further
confirmatory studies. Additionally this study will evaluate the association between CPD SNPs
genotypes and response to perindopril; the effect of perindopril in waist circumference,
waist/hip ratio, and BMI and the tolerability and safety of perindopril in the study
population.